Astrazeneca Pharma India is currently trading at Rs. 945.00, up by 21.70 points or 2.35 % from its previous closing of Rs. 923.30 on the BSE.
The scrip opened at Rs. 952.50 and has touched a high and low of Rs. 970.55 and Rs. 944.10 respectively. So far 2912 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 1245.00 on 23-Jun-2014 and a 52 week low of Rs. 785.30 on 17-Dec-2014.
Last one week high and low of the scrip stood at Rs. 940.00 and Rs. 865.00 respectively. The current market cap of the company is Rs. 2360.25 crore.
The promoters holding in the company stood at 75.00 % while Institutions and Non-Institutions held 15.69 % and 9.31 % respectively.
AstraZeneca Pharma India has entered into agreement with AstraZeneca UK (AZ UK) pursuant to which the company would receive from AZ UK, the reimbursement of certain costs incurred for the marketing and promotion of the new launch products and support for the distribution of other products supplied by AZ UK, in accordance with the arm s length return on revenues.
Recently, AstraZeneca entered into five-year research collaboration with the Harvard Stem Cell Institute (HSCI) to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1473.65 |
Dr. Reddys Lab | 5956.70 |
Cipla | 1480.25 |
Zydus Lifesciences | 1037.85 |
Lupin | 1591.00 |
View more.. |